Department of Health Care Management, University of Pennsylvania, Philadelphia, PA, USA.
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA.
J Natl Cancer Inst. 2023 Feb 8;115(2):125-130. doi: 10.1093/jnci/djac194.
The Oncology Care Model (OCM), launched in 2016 by the Centers for Medicare and Medicaid Services, was the first demonstration of value-based payment in oncology. Although the OCM delivered mixed results in terms of quality of care and total episode costs, the model had no statistically significant impact on remediating racial, ethnic, and socioeconomic disparities among beneficiaries. These deficits have been prominent in other aspects of US healthcare, and as a result, the Institute for Healthcare Improvement has advocated for stakeholders to leverage improvement science, an applied science that focuses on implementing rapid cycles for change, to identify and overcome barriers to health equity. With the announcement of the new Enhancing Oncology Model, a continuation of the OCM's efforts in introducing value to cancer care for episodes surrounding chemotherapy administration, both policymakers and providers must apply tenets of improvement science and make eliminating disparities in alternative payment models a forefront objective. In this commentary, we discuss previous inequities in alternative payment models, the role that improvement science plays in addressing health-care disparities, and steps that stakeholders can take to maximize equitable outcomes in the Enhancing Oncology Model.
肿瘤学照护模式(Oncology Care Model,OCM)于 2016 年由医疗保险和医疗补助服务中心推出,是肿瘤学领域首个基于价值的支付方式的范例。尽管 OCM 在改善医疗质量和总治疗费用方面的效果参差不齐,但该模式对改善受益人之间的种族、民族和社会经济差异并没有统计学上的显著影响。这些缺陷在美国医疗保健的其他方面也很突出,因此,医疗改进研究所倡导利益相关者利用改善科学,这是一种专注于实施快速变革周期的应用科学,以确定和克服健康公平的障碍。随着新的强化肿瘤学模式的宣布,OCM 继续努力为化疗管理相关的治疗带来价值,政策制定者和提供者都必须应用改善科学的原则,并将消除差异纳入替代支付模式的首要目标。在这篇评论中,我们讨论了之前在替代支付模式方面的不平等现象、改善科学在解决医疗保健差异方面所扮演的角色,以及利益相关者可以采取的措施,以在强化肿瘤学模式中实现公平结果的最大化。